PARP-1抑制剂对BRCA1基因沉默的乳腺癌细胞株MCF-7及PTEN基因沉默的前列腺癌细胞株22RV1增殖的影响

doi:10.6040/j.issn.1671-7554.0.2015.648

Abstract

Abstract: Objective To evaluate the proliferative effects of poly(ADP-ribose)polymerase-1(PARP-1)inhibitor on breast cancer cell line MCF-7 with breast cancer susceptibility(BRCA)genes silencing and prostate cancer cell line 22RV1 with phosphatase and tensin homology deleted on chromosome ten(PTEN)silencing. Methods BRCA1/PTEN-targeted small interfering double-stranded RNAs(siRNA)were introduced into MCF-7/22RV1 cells by Lipofectamine TM2000A, respectively. The viability of cells treated with PARP inhibitor was measured by CCK-8 assay. Cell distribution of cell cycle was determined by flow cytometry. Levels of BRCA1, PTEN, RAD51, PARP, and NF-κB protein were measured by Western blotting. Results PARP inhibitor AG014699 inhibited the proliferation of MCF-7 with BRCA1 genes silencing and 22RV1 with PTEN silencing in a concentration and time-dependent manner, and blocked the cell cycle in G2/M. RAD51 and NF-κB protein expressions in the proliferation of MCF-7 with BRCA1 genes silencing and 22RV1 with PTEN silencing were decreased. Conclusion Significant growth inhibition could be observed upon PARP inhibitor AG014699 in cells with BRCA1 and PTEN-associated DNA repair defects, indicating that AG014699 山东大学学报 (医学版)54卷5期 - 刘相永,等.PARP-1抑制剂对BRCA1基因沉默的乳腺癌细胞株MCF-7及PTEN基因沉默的前列腺癌细胞株22RV1增殖的影响 \=-could markedly inhibit the proliferation of cells possibly due to the attenuation of RAD51 and NF-κB activity.

Key words: Poly(ADP-ribose)polymerase, Breast cancer susceptibility genes, Nuclear factor κB, RAD51, Phosphatase and tensin homology deleted on chromosome ten

CLC Number:

R73-36+1

LIU Xiangyong, SUN Ying, LI Li. The effects of poly(ADP-ribose)polymerase inhibitor on the proliferation of breast cancer cell line MCF-7 and prostate cancer cell line 22RV1 with BRCA and PTEN gene silencing[J].JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 6-11.

References

[1] Ashworth A. A synthetic lethal therapeutic approach:poly(ADP)ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair[J]. J Clin Oncol, 2008, 26(22):3785-3790.
[2] Djordjevic B, Barkoh BA, Luthra R, et al. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma:retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas[J]. Mod Pathol, 2013, 26(10):1401-1412.
[3] Broering TJ, Alavattam KG, Sadreyev RI, et al. BRCA1 establishes DNA damage signaling and pericentric heterochromatin of the X chromosome in male meiosis[J]. J Cell Biol, 2014, 205(5):663-675.
[4] Hill SJ, Clark AP, Silver DP, et al. BRCA1 pathway function in basal-like breast cancer cells[J]. Mol Cell Biol, 2014, 34(20):3828-3842.
[5] Martin-Oliva D, OValle F, Munoz-Gamez JA, et al. Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia[J]. Oncogene, 2004, 23(31):5275-5283.
[6] Hassa PO, Buerki C, Lombardi C, et al. Transcriptional coactivation of nuclear factor-kappaB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1[J]. J Biol Chem, 2003, 278(46):45145-45153.
[7] Miao D, Xin C, Hai X, et al. Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene[J]. PLoS One, 2012, 7(4):e35153. doi:10.1371/journal.pone.0035153. Epub 2012 Apr 11.
[8] Hui W, Chang QL, Yan T, et al. Effect of adriamycin on BRCA1 and PARP-1 expression in MCF-7 breast cancer cells[J]. Int J Clin Exp Pathol, 2014, 7(9):5909-5915.
[9] Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer[J]. J Clin Oncol, 2008, 26(26):4282-4288.
[10] 孙颖, 丁焕, 黎晓晴, 等. 多聚腺苷二磷酸核糖聚合酶抑制剂AG014699联合化疗对三阴性乳腺癌细胞株MDA-MB-231增殖的影响[J]. 中国医学科学院学报, 2014, 36(2):135-139. SUN Ying, DING Huan, LI Xiaoqing, et al. Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231[J]. Acta Academiae Medicinae Sinicae, 2014, 36(2):135-139.
[11] Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation[J]. Br J Cancer, 2011, 105(8):1114-1122.
[12] McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose)polymerase inhibition[J]. Cancer Res, 2006, 66(16):8109-8115.
[13] Hegana DC, Lua Y, Stacheleka GC, et al. Inhibition of poly(ADP-ribose)polymerase downregulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130[J]. PNAS, 2010, 107(5):2201-2206.
[14] Somyajit K, Basavaraju S, Scully R, et al. ATM- and ATR-mediated phosphorylation of XRCC3 regulates DNA double-strand break-induced checkpoint activation and repair[J]. Mol Cell Biol, 2013, 33(9):1830-1844.
[15] Ta HQ, Gioeli D. The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer[J]. Endocr Relat Cancer, 2014, 21(5):R395-407.
[16] Smith J, Tho LM, Xu N, et al. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer[J]. Adv Cancer Res, 2010, 108:73-112. doi:10.1016/B978-0-12-380888-2.00003-0.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!

The effects of poly(ADP-ribose)polymerase inhibitor on the proliferation of breast cancer cell line MCF-7 and prostate cancer cell line 22RV1 with BRCA and PTEN gene silencing

PDF (PC)

Abstract

Cite this article

share this article

References

Related Articles 3

Metrics

Comments

Recommended 0

[1]	LIN Xueyan, LI Chunyan, HOU Xiaoman, TIAN Yongjie. Expressions of PARP-1 and EMT markers in eutopic and ectopic endometrium of adenomyosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 36-40.
[2]	CHEN Jianhua, ZHU Banghao. Inhibiting Effect of ginsenoside Re on the expression of PARP-1 in human umbilical vein endothelial cell [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 34-38.
[3]	ZHANG Jing-jing1, WANG Zhe1, TIAN Yong-jie1, ZHANG Jie2. Effects of PJ34 on growth activity and cisplatin resistance of ovarian cancer C13* cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 46-50.